SLC1A5 and Miyoshi myopathy: Inhibition of aerobic glycolysis with dichloroacetate (DCA), glutamine transport by targeting ASCT2 or glutaminase with CB-839 increases sensitivity to bortezomib in MM (29, 179, 180).